Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RILUSCI
2024-514882-20-00Phase 2Authorised
- Sponsor
- Assistance Publique–Hôpitaux de Marseille
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Muscle spasm and spinal cord injury (SCI) comparing Riluzole with Placebo (2 arms). Primary endpoint: Primary: Improvement in spasticity at Week 2. Planned start Jul 2024; status: authorised.
02
Drugs
riluzole
03
Conditions
Muscle spasmspinal cord injury (SCI)
Beyond the preview
Go deeper on 2024-514882-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514882-20-00.